Heterologous AD5-nCOV plus CoronaVac versus homologous CoronaVac vaccination: a randomized phase 4 trial
The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants and the waning of vaccine-elicited neutralizing antibodies suggests that additional coronavirus disease 2019 (COVID-19) vaccine doses may be needed for individuals who initially received CoronaVac. We evaluated th...
Gespeichert in:
| Veröffentlicht in: | Nature medicine Jg. 28; H. 2; S. 401 - 409 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , |
| Format: | Journal Article |
| Sprache: | Englisch |
| Veröffentlicht: |
New York
Nature Publishing Group US
01.02.2022
Nature Publishing Group |
| Schlagworte: | |
| ISSN: | 1078-8956, 1546-170X, 1546-170X |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Abstract | The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants and the waning of vaccine-elicited neutralizing antibodies suggests that additional coronavirus disease 2019 (COVID-19) vaccine doses may be needed for individuals who initially received CoronaVac. We evaluated the safety and immunogenicity of the recombinant adenovirus type 5 (AD5)-vectored COVID-19 vaccine Convidecia as a heterologous booster versus those of CoronaVac as homologous booster in adults previously vaccinated with CoronaVac in an ongoing, randomized, observer-blinded, parallel-controlled phase 4 trial (
NCT04892459
). Adults who had received two doses of CoronaVac in the past 3–6 months were vaccinated with Convidecia (
n
= 96) or CoronaVac (
n
= 102). Adults who had received one dose of CoronaVac in the past 1–3 months were also vaccinated with Convidecia (
n
= 51) or CoronaVac (
n
= 50). The co-primary endpoints were the occurrence of adverse reactions within 28 d after vaccination and geometric mean titers (GMTs) of neutralizing antibodies against live wild-type SARS-CoV-2 virus at 14 d after booster vaccination. Adverse reactions after vaccination were significantly more frequent in Convidecia recipients but were generally mild to moderate in all treatment groups. Heterologous boosting with Convidecia elicited significantly increased GMTs of neutralizing antibody against SARS-CoV-2 than homologous boosting with CoronaVac in participants who had previously received one or two doses of CoronaVac. These data suggest that heterologous boosting with Convidecia following initial vaccination with CoronaVac is safe and more immunogenic than homologous boosting.
Heterologous vaccination with Convidecia, a recombinant adenovirus type 5-vectored COVID-19 vaccine, after one or two doses of CoronaVac, an inactivated SARS-CoV-2 vaccine, is more reactogenic but elicits significantly higher levels of neutralizing antibodies than homologous vaccination. |
|---|---|
| AbstractList | The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants and the waning of vaccine-elicited neutralizing antibodies suggests that additional coronavirus disease 2019 (COVID-19) vaccine doses may be needed for individuals who initially received CoronaVac. We evaluated the safety and immunogenicity of the recombinant adenovirus type 5 (AD5)-vectored COVID-19 vaccine Convidecia as a heterologous booster versus those of CoronaVac as homologous booster in adults previously vaccinated with CoronaVac in an ongoing, randomized, observer-blinded, parallel-controlled phase 4 trial (NCT04892459). Adults who had received two doses of CoronaVac in the past 3–6 months were vaccinated with Convidecia (n = 96) or CoronaVac (n = 102). Adults who had received one dose of CoronaVac in the past 1–3 months were also vaccinated with Convidecia (n = 51) or CoronaVac (n = 50). The co-primary endpoints were the occurrence of adverse reactions within 28 d after vaccination and geometric mean titers (GMTs) of neutralizing antibodies against live wild-type SARS-CoV-2 virus at 14 d after booster vaccination. Adverse reactions after vaccination were significantly more frequent in Convidecia recipients but were generally mild to moderate in all treatment groups. Heterologous boosting with Convidecia elicited significantly increased GMTs of neutralizing antibody against SARS-CoV-2 than homologous boosting with CoronaVac in participants who had previously received one or two doses of CoronaVac. These data suggest that heterologous boosting with Convidecia following initial vaccination with CoronaVac is safe and more immunogenic than homologous boosting. Heterologous vaccination with Convidecia, a recombinant adenovirus type 5-vectored COVID-19 vaccine, after one or two doses of CoronaVac, an inactivated SARS-CoV-2 vaccine, is more reactogenic but elicits significantly higher levels of neutralizing antibodies than homologous vaccination. The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants and the waning of vaccine-elicited neutralizing antibodies suggests that additional coronavirus disease 2019 (COVID-19) vaccine doses may be needed for individuals who initially received CoronaVac. We evaluated the safety and immunogenicity of the recombinant adenovirus type 5 (AD5)-vectored COVID-19 vaccine Convidecia as a heterologous booster versus those of CoronaVac as homologous booster in adults previously vaccinated with CoronaVac in an ongoing, randomized, observer-blinded, parallel-controlled phase 4 trial ( NCT04892459 ). Adults who had received two doses of CoronaVac in the past 3-6 months were vaccinated with Convidecia (n = 96) or CoronaVac (n = 102). Adults who had received one dose of CoronaVac in the past 1-3 months were also vaccinated with Convidecia (n = 51) or CoronaVac (n = 50). The co-primary endpoints were the occurrence of adverse reactions within 28 d after vaccination and geometric mean titers (GMTs) of neutralizing antibodies against live wild-type SARS-CoV-2 virus at 14 d after booster vaccination. Adverse reactions after vaccination were significantly more frequent in Convidecia recipients but were generally mild to moderate in all treatment groups. Heterologous boosting with Convidecia elicited significantly increased GMTs of neutralizing antibody against SARS-CoV-2 than homologous boosting with CoronaVac in participants who had previously received one or two doses of CoronaVac. These data suggest that heterologous boosting with Convidecia following initial vaccination with CoronaVac is safe and more immunogenic than homologous boosting.The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants and the waning of vaccine-elicited neutralizing antibodies suggests that additional coronavirus disease 2019 (COVID-19) vaccine doses may be needed for individuals who initially received CoronaVac. We evaluated the safety and immunogenicity of the recombinant adenovirus type 5 (AD5)-vectored COVID-19 vaccine Convidecia as a heterologous booster versus those of CoronaVac as homologous booster in adults previously vaccinated with CoronaVac in an ongoing, randomized, observer-blinded, parallel-controlled phase 4 trial ( NCT04892459 ). Adults who had received two doses of CoronaVac in the past 3-6 months were vaccinated with Convidecia (n = 96) or CoronaVac (n = 102). Adults who had received one dose of CoronaVac in the past 1-3 months were also vaccinated with Convidecia (n = 51) or CoronaVac (n = 50). The co-primary endpoints were the occurrence of adverse reactions within 28 d after vaccination and geometric mean titers (GMTs) of neutralizing antibodies against live wild-type SARS-CoV-2 virus at 14 d after booster vaccination. Adverse reactions after vaccination were significantly more frequent in Convidecia recipients but were generally mild to moderate in all treatment groups. Heterologous boosting with Convidecia elicited significantly increased GMTs of neutralizing antibody against SARS-CoV-2 than homologous boosting with CoronaVac in participants who had previously received one or two doses of CoronaVac. These data suggest that heterologous boosting with Convidecia following initial vaccination with CoronaVac is safe and more immunogenic than homologous boosting. The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants and the waning of vaccine-elicited neutralizing antibodies suggests that additional coronavirus disease 2019 (COVID-19) vaccine doses may be needed for individuals who initially received CoronaVac. We evaluated the safety and immunogenicity of the recombinant adenovirus type 5 (AD5)-vectored COVID-19 vaccine Convidecia as a heterologous booster versus those of CoronaVac as homologous booster in adults previously vaccinated with CoronaVac in an ongoing, randomized, observer-blinded, parallel-controlled phase 4 trial ( NCT04892459 ). Adults who had received two doses of CoronaVac in the past 3-6 months were vaccinated with Convidecia (n = 96) or CoronaVac (n = 102). Adults who had received one dose of CoronaVac in the past 1-3 months were also vaccinated with Convidecia (n = 51) or CoronaVac (n = 50). The co-primary endpoints were the occurrence of adverse reactions within 28 d after vaccination and geometric mean titers (GMTs) of neutralizing antibodies against live wild-type SARS-CoV-2 virus at 14 d after booster vaccination. Adverse reactions after vaccination were significantly more frequent in Convidecia recipients but were generally mild to moderate in all treatment groups. Heterologous boosting with Convidecia elicited significantly increased GMTs of neutralizing antibody against SARS-CoV-2 than homologous boosting with CoronaVac in participants who had previously received one or two doses of CoronaVac. These data suggest that heterologous boosting with Convidecia following initial vaccination with CoronaVac is safe and more immunogenic than homologous boosting. The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants and the waning of vaccine-elicited neutralizing antibodies suggests that additional coronavirus disease 2019 (COVID-19) vaccine doses may be needed for individuals who initially received CoronaVac. We evaluated the safety and immunogenicity of the recombinant adenovirus type 5 (AD5)-vectored COVID-19 vaccine Convidecia as a heterologous booster versus those of CoronaVac as homologous booster in adults previously vaccinated with CoronaVac in an ongoing, randomized, observer-blinded, parallel-controlled phase 4 trial ( NCT04892459 ). Adults who had received two doses of CoronaVac in the past 3–6 months were vaccinated with Convidecia ( n = 96) or CoronaVac ( n = 102). Adults who had received one dose of CoronaVac in the past 1–3 months were also vaccinated with Convidecia ( n = 51) or CoronaVac ( n = 50). The co-primary endpoints were the occurrence of adverse reactions within 28 d after vaccination and geometric mean titers (GMTs) of neutralizing antibodies against live wild-type SARS-CoV-2 virus at 14 d after booster vaccination. Adverse reactions after vaccination were significantly more frequent in Convidecia recipients but were generally mild to moderate in all treatment groups. Heterologous boosting with Convidecia elicited significantly increased GMTs of neutralizing antibody against SARS-CoV-2 than homologous boosting with CoronaVac in participants who had previously received one or two doses of CoronaVac. These data suggest that heterologous boosting with Convidecia following initial vaccination with CoronaVac is safe and more immunogenic than homologous boosting. The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants and the waning of vaccine-elicited neutralizing antibodies suggests that additional coronavirus disease 2019 (COVID-19) vaccine doses may be needed for individuals who initially received CoronaVac. We evaluated the safety and immunogenicity of the recombinant adenovirus type 5 (AD5)-vectored COVID-19 vaccine Convidecia as a heterologous booster versus those of CoronaVac as homologous booster in adults previously vaccinated with CoronaVac in an ongoing, randomized, observer-blinded, parallel-controlled phase 4 trial ( NCT04892459 ). Adults who had received two doses of CoronaVac in the past 3–6 months were vaccinated with Convidecia ( n = 96) or CoronaVac ( n = 102). Adults who had received one dose of CoronaVac in the past 1–3 months were also vaccinated with Convidecia ( n = 51) or CoronaVac ( n = 50). The co-primary endpoints were the occurrence of adverse reactions within 28 d after vaccination and geometric mean titers (GMTs) of neutralizing antibodies against live wild-type SARS-CoV-2 virus at 14 d after booster vaccination. Adverse reactions after vaccination were significantly more frequent in Convidecia recipients but were generally mild to moderate in all treatment groups. Heterologous boosting with Convidecia elicited significantly increased GMTs of neutralizing antibody against SARS-CoV-2 than homologous boosting with CoronaVac in participants who had previously received one or two doses of CoronaVac. These data suggest that heterologous boosting with Convidecia following initial vaccination with CoronaVac is safe and more immunogenic than homologous boosting. Heterologous vaccination with Convidecia, a recombinant adenovirus type 5-vectored COVID-19 vaccine, after one or two doses of CoronaVac, an inactivated SARS-CoV-2 vaccine, is more reactogenic but elicits significantly higher levels of neutralizing antibodies than homologous vaccination. |
| Author | Song, Zhizhou Shi, Fengjuan Cui, Lunbiao Wang, Xuewen Jin, Lairun Xu, Xiaoyu Pan, Hongxing Zhu, Jiahong Chen, Wei Li, Jingxin Jin, Pengfei Wang, Xue Liu, Jingxian Zhu, Tao Chen, Yin Guo, Xiling Li, Junqiang Zhu, Fengcai Wu, Shipo Wan, Jingxuan Hou, Lihua |
| Author_xml | – sequence: 1 givenname: Jingxin surname: Li fullname: Li, Jingxin organization: NHC Key Laboratory of Enteric Pathogenic Microbiology, Jiangsu Provincial Center for Disease Control and Prevention, Institute of Global Health and Emergency Pharmacy, China Pharmaceutical University – sequence: 2 givenname: Lihua orcidid: 0000-0001-7366-8974 surname: Hou fullname: Hou, Lihua organization: Institute of Biotechnology, Academy of Military Medical Sciences – sequence: 3 givenname: Xiling surname: Guo fullname: Guo, Xiling organization: NHC Key Laboratory of Enteric Pathogenic Microbiology, Jiangsu Provincial Center for Disease Control and Prevention – sequence: 4 givenname: Pengfei surname: Jin fullname: Jin, Pengfei organization: NHC Key Laboratory of Enteric Pathogenic Microbiology, Jiangsu Provincial Center for Disease Control and Prevention – sequence: 5 givenname: Shipo orcidid: 0000-0001-8083-247X surname: Wu fullname: Wu, Shipo organization: Institute of Biotechnology, Academy of Military Medical Sciences – sequence: 6 givenname: Jiahong surname: Zhu fullname: Zhu, Jiahong organization: Lianshui County Center for Disease Control and Prevention – sequence: 7 givenname: Hongxing surname: Pan fullname: Pan, Hongxing organization: NHC Key Laboratory of Enteric Pathogenic Microbiology, Jiangsu Provincial Center for Disease Control and Prevention – sequence: 8 givenname: Xue surname: Wang fullname: Wang, Xue organization: CanSino Biologics Inc – sequence: 9 givenname: Zhizhou surname: Song fullname: Song, Zhizhou organization: Lianshui County Center for Disease Control and Prevention – sequence: 10 givenname: Jingxuan surname: Wan fullname: Wan, Jingxuan organization: CanSino Biologics Inc – sequence: 11 givenname: Lunbiao surname: Cui fullname: Cui, Lunbiao organization: NHC Key Laboratory of Enteric Pathogenic Microbiology, Jiangsu Provincial Center for Disease Control and Prevention – sequence: 12 givenname: Junqiang surname: Li fullname: Li, Junqiang organization: CanSino Biologics Inc – sequence: 13 givenname: Yin surname: Chen fullname: Chen, Yin organization: NHC Key Laboratory of Enteric Pathogenic Microbiology, Jiangsu Provincial Center for Disease Control and Prevention – sequence: 14 givenname: Xuewen surname: Wang fullname: Wang, Xuewen organization: Canming Medical Technology Co., Ltd – sequence: 15 givenname: Lairun surname: Jin fullname: Jin, Lairun organization: Department of Public Health, Southeast University – sequence: 16 givenname: Jingxian surname: Liu fullname: Liu, Jingxian organization: NHC Key Laboratory of Enteric Pathogenic Microbiology, Jiangsu Provincial Center for Disease Control and Prevention – sequence: 17 givenname: Fengjuan surname: Shi fullname: Shi, Fengjuan organization: NHC Key Laboratory of Enteric Pathogenic Microbiology, Jiangsu Provincial Center for Disease Control and Prevention – sequence: 18 givenname: Xiaoyu surname: Xu fullname: Xu, Xiaoyu organization: Vazyme Biotech Co., Ltd – sequence: 19 givenname: Tao surname: Zhu fullname: Zhu, Tao organization: CanSino Biologics Inc – sequence: 20 givenname: Wei orcidid: 0000-0001-5805-2469 surname: Chen fullname: Chen, Wei email: cw0226@foxmail.com organization: Institute of Biotechnology, Academy of Military Medical Sciences – sequence: 21 givenname: Fengcai orcidid: 0000-0002-1644-0006 surname: Zhu fullname: Zhu, Fengcai email: jszfc@vip.sina.com organization: NHC Key Laboratory of Enteric Pathogenic Microbiology, Jiangsu Provincial Center for Disease Control and Prevention, Institute of Global Health and Emergency Pharmacy, China Pharmaceutical University, Center for Global Health, Nanjing Medical University |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/35087233$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kUtPxCAUhYnR-Bj9Ay5MEzduqlCgUBcmk_GZmLhR444w9HYG08IIHRPn14uO74ULAhe-czk3ZwutOu8AoV2CDwmm8igywiuS4yItUgqRL1bQJuGszInAD6vpjIXMZcXLDbQV4yPGmGJeraMNyrEUBaWbaHoJPQTf-omfx2x4ynM3urnPZm2qRj54p--1yZ4hxHQx9d0n-eNNG2Od7q13x5nOgna17-wC6mw21REylvXB6nYbrTW6jbDzsQ_Q3fnZ7egyv765uBoNr3PDGe5ziWvWjEEyI4AbwmRdispQGPOxaXBRE91UsmqEkYRSxmhtNGFccEx4qimnA3Sy7DubjzuoDbg-6FbNgu10eFFeW_X7xdmpmvhnJWVJuaCpwcFHg-Cf5hB71dlooG21gzS5KsqCyopJWSR0_w_66OfBpfESRYlgQiaLA7T309GXlc8QElAsARN8jAGaL4Rg9Za0WiatUtLqPWm1SCL5R2Rs_55Cmsq2_0vpUhrTP24C4dv2P6pXF8K-ew |
| CitedBy_id | crossref_primary_10_1038_s41467_023_40489_2 crossref_primary_10_1080_14760584_2024_2320861 crossref_primary_10_3389_fpubh_2022_960598 crossref_primary_10_1001_jamanetworkopen_2022_53301 crossref_primary_10_3390_vaccines12020155 crossref_primary_10_3389_fimmu_2023_1244373 crossref_primary_10_1016_j_vaccine_2024_03_005 crossref_primary_10_1080_21645515_2023_2267869 crossref_primary_10_1002_mco2_188 crossref_primary_10_1016_j_cytogfr_2023_11_004 crossref_primary_10_3389_fimmu_2022_918896 crossref_primary_10_1007_s11356_022_22661_1 crossref_primary_10_4103_2773_0344_362641 crossref_primary_10_3389_fimmu_2022_1017590 crossref_primary_10_1002_jmv_70326 crossref_primary_10_3389_fpubh_2022_1046546 crossref_primary_10_1038_s41392_022_01295_2 crossref_primary_10_3390_biom13111565 crossref_primary_10_1016_j_ijbiomac_2024_134012 crossref_primary_10_1007_s12038_023_00355_1 crossref_primary_10_3390_v16010052 crossref_primary_10_1002_jmv_29161 crossref_primary_10_4014_jmb_2411_11059 crossref_primary_10_3389_fimmu_2022_967051 crossref_primary_10_1016_j_virol_2024_110026 crossref_primary_10_1038_s41392_022_00984_2 crossref_primary_10_1080_14760584_2022_2119133 crossref_primary_10_1186_s12879_023_08768_x crossref_primary_10_1590_0037_8682_0046_2023 crossref_primary_10_3390_microorganisms10071450 crossref_primary_10_1089_vim_2024_0076 crossref_primary_10_3390_jcm11144164 crossref_primary_10_1016_S2213_2600_23_00049_8 crossref_primary_10_1038_s41590_022_01248_5 crossref_primary_10_5582_bst_2022_01062 crossref_primary_10_1038_s41392_024_01751_1 crossref_primary_10_1128_msystems_00927_22 crossref_primary_10_1038_s41392_022_00996_y crossref_primary_10_1080_22221751_2024_2320913 crossref_primary_10_3389_fimmu_2023_1239179 crossref_primary_10_1016_j_clim_2023_109342 crossref_primary_10_1038_s41541_022_00597_4 crossref_primary_10_3389_fimmu_2024_1461419 crossref_primary_10_1002_jmv_28806 crossref_primary_10_1016_S1473_3099_25_00005_2 crossref_primary_10_1080_21645515_2023_2209919 crossref_primary_10_1016_j_apsb_2024_12_030 crossref_primary_10_1016_j_biopha_2022_114208 crossref_primary_10_1002_jmv_29625 crossref_primary_10_1128_mmbr_00260_24 crossref_primary_10_1016_j_mayocp_2025_03_017 crossref_primary_10_1016_S2213_2600_22_00087_X crossref_primary_10_3390_pathogens12101254 crossref_primary_10_3390_pathogens11091035 crossref_primary_10_3389_fimmu_2023_1142394 crossref_primary_10_1038_s41392_022_01079_8 crossref_primary_10_1080_21645515_2023_2273155 crossref_primary_10_1080_14760584_2024_2425283 crossref_primary_10_1038_s41392_024_01917_x crossref_primary_10_3389_fimmu_2022_965971 crossref_primary_10_1016_S1473_3099_23_00350_X crossref_primary_10_1016_j_hlife_2023_12_005 crossref_primary_10_3389_fimmu_2022_949248 crossref_primary_10_3390_ijerph191710752 crossref_primary_10_1038_s41541_025_01155_4 crossref_primary_10_1002_jmv_27697 crossref_primary_10_1038_s41467_022_30864_w crossref_primary_10_1038_s41541_024_00857_5 crossref_primary_10_1186_s12916_023_02942_3 crossref_primary_10_1016_j_imlet_2022_10_002 crossref_primary_10_3389_fimmu_2023_1282612 crossref_primary_10_3390_pathogens12050655 crossref_primary_10_1080_14760584_2023_2234997 crossref_primary_10_1016_j_vaccine_2023_06_080 crossref_primary_10_1080_14760584_2024_2315089 crossref_primary_10_1186_s12929_022_00853_8 crossref_primary_10_1080_14760584_2023_2274491 crossref_primary_10_3390_vaccines12020120 crossref_primary_10_3390_vaccines10081321 crossref_primary_10_1016_j_lanwpc_2023_100829 crossref_primary_10_1093_infdis_jiad134 crossref_primary_10_1097_CM9_0000000000002567 crossref_primary_10_3389_fcimb_2022_978440 crossref_primary_10_1002_jmv_29640 crossref_primary_10_1016_j_heliyon_2023_e13952 crossref_primary_10_3390_vaccines10101655 crossref_primary_10_1186_s12916_024_03471_3 crossref_primary_10_1155_2023_7598307 crossref_primary_10_1016_S1473_3099_23_00199_8 crossref_primary_10_3390_vaccines10111924 crossref_primary_10_1080_14760584_2023_2242528 crossref_primary_10_1186_s12879_024_09293_1 crossref_primary_10_3389_fpubh_2022_943876 crossref_primary_10_1038_s41392_023_01408_5 crossref_primary_10_3389_fpubh_2022_929407 crossref_primary_10_1080_21645515_2023_2194189 crossref_primary_10_1016_j_virol_2025_110394 crossref_primary_10_3201_eid3001_230414 crossref_primary_10_1080_14760584_2025_2550984 crossref_primary_10_1016_j_virs_2022_12_008 crossref_primary_10_1080_22221751_2022_2095931 crossref_primary_10_1128_spectrum_00102_23 crossref_primary_10_1186_s12879_024_09158_7 crossref_primary_10_1002_jmv_28329 crossref_primary_10_1126_scitranslmed_ade6023 crossref_primary_10_1080_22221751_2024_2332660 crossref_primary_10_1002_jmv_29542 crossref_primary_10_1002_mco2_238 crossref_primary_10_3390_vaccines11121815 crossref_primary_10_3390_vaccines11030706 crossref_primary_10_1016_j_heliyon_2023_e15679 crossref_primary_10_3390_vaccines11050896 |
| Cites_doi | 10.1016/j.vaccine.2015.11.062 10.1080/22221751.2021.1902245 10.1056/NEJMoa2107715 10.1016/S2213-2600(21)00220-4 10.1016/S0167-5699(00)01612-1 10.1016/j.immuni.2010.10.008 10.1016/S0140-6736(21)00234-8 10.1038/s41591-021-01560-x 10.1016/j.coi.2009.05.016 10.1016/S0140-6736(20)31605-6 10.1016/S0140-6736(20)31866-3 10.1016/S0140-6736(21)01115-6 10.1016/S0140-6736(21)02753-7 10.1016/S0140-6736(21)01429-X 10.1080/14760584.2019.1640117 10.1016/S0140-6736(21)00527-4 10.1016/S1473-3099(20)30120-1 10.1101/2021.10.10.21264827 10.2139/ssrn.3822780 10.1016/S2666-5247(21)00177-4 10.1016/j.eclinm.2021.101036 10.1016/S0140-6736(21)01694-9 10.1056/NEJMc2110716 10.1016/s1473-3099(21)00681-2 10.1093/cid/ciab845 10.1101/2021.05.19.21257334 10.1007/978-3-642-14691-6 |
| ContentType | Journal Article |
| Copyright | The Author(s) 2022 2022. The Author(s). The Author(s) 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| Copyright_xml | – notice: The Author(s) 2022 – notice: 2022. The Author(s). – notice: The Author(s) 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| DBID | C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7QG 7QL 7QP 7QR 7T5 7TK 7TM 7TO 7U7 7U9 7X7 7XB 88A 88E 88I 8AO 8FD 8FE 8FH 8FI 8FJ 8FK 8G5 ABUWG AEUYN AFKRA AZQEC BBNVY BENPR BHPHI C1K CCPQU DWQXO FR3 FYUFA GHDGH GNUQQ GUQSH H94 HCIFZ K9. LK8 M0S M1P M2O M2P M7N M7P MBDVC P64 PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS Q9U RC3 7X8 5PM |
| DOI | 10.1038/s41591-021-01677-z |
| DatabaseName | Springer Nature OA Free Journals CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Animal Behavior Abstracts Bacteriology Abstracts (Microbiology B) Calcium & Calcified Tissue Abstracts Chemoreception Abstracts Immunology Abstracts Neurosciences Abstracts Nucleic Acids Abstracts Oncogenes and Growth Factors Abstracts Toxicology Abstracts Virology and AIDS Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Biology Database (Alumni Edition) Medical Database (Alumni Edition) Science Database (Alumni Edition) ProQuest Pharma Collection Technology Research Database ProQuest SciTech Collection ProQuest Natural Science Collection ProQuest Hospital Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Research Library ProQuest Central (Alumni) ProQuest One Sustainability ProQuest Central UK/Ireland ProQuest Central Essentials - QC Biological Science Collection ProQuest Central Natural Science Collection Environmental Sciences and Pollution Management ProQuest One Community College ProQuest Central Engineering Research Database Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student ProQuest Research Library AIDS and Cancer Research Abstracts SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) Biological Sciences Health & Medical Collection (Alumni) Medical Database Research Library Science Database Algology Mycology and Protozoology Abstracts (Microbiology C) Biological Science Database Research Library (Corporate) Biotechnology and BioEngineering Abstracts ProQuest Central Premium ProQuest One Academic (New) ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China ProQuest Central Basic Genetics Abstracts MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Research Library Prep ProQuest Central Student Oncogenes and Growth Factors Abstracts ProQuest Central Essentials Nucleic Acids Abstracts SciTech Premium Collection ProQuest Central China Environmental Sciences and Pollution Management ProQuest One Applied & Life Sciences ProQuest One Sustainability Health Research Premium Collection Natural Science Collection Health & Medical Research Collection Biological Science Collection Chemoreception Abstracts ProQuest Central (New) ProQuest Medical Library (Alumni) Virology and AIDS Abstracts ProQuest Science Journals (Alumni Edition) ProQuest Biological Science Collection ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database Neurosciences Abstracts ProQuest Hospital Collection (Alumni) Biotechnology and BioEngineering Abstracts ProQuest Health & Medical Complete ProQuest One Academic UKI Edition Engineering Research Database ProQuest One Academic Calcium & Calcified Tissue Abstracts ProQuest One Academic (New) Technology Research Database ProQuest One Academic Middle East (New) ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing Research Library (Alumni Edition) ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Biology Journals (Alumni Edition) ProQuest Central ProQuest Health & Medical Research Collection Genetics Abstracts Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Bacteriology Abstracts (Microbiology B) Algology Mycology and Protozoology Abstracts (Microbiology C) AIDS and Cancer Research Abstracts ProQuest Research Library ProQuest Central Basic Toxicology Abstracts ProQuest Science Journals ProQuest SciTech Collection ProQuest Medical Library Animal Behavior Abstracts Immunology Abstracts ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE Research Library Prep CrossRef |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Biology |
| EISSN | 1546-170X |
| EndPage | 409 |
| ExternalDocumentID | PMC8863573 35087233 10_1038_s41591_021_01677_z |
| Genre | Randomized Controlled Trial Research Support, Non-U.S. Gov't Journal Article Clinical Trial, Phase IV |
| GeographicLocations | China |
| GeographicLocations_xml | – name: China |
| GrantInformation_xml | – fundername: Jiangsu Provincial Key Research and Development Program, BE2021738 – fundername: National Natural Science Foundation of China (National Science Foundation of China) grantid: 82173584 funderid: https://doi.org/10.13039/501100001809 – fundername: National Natural Science Foundation of China (National Science Foundation of China) grantid: 82173584 – fundername: ; – fundername: ; grantid: 82173584 |
| GroupedDBID | --- .-4 .55 .GJ 0R~ 123 1CY 29M 2FS 36B 39C 3O- 3V. 4.4 53G 5BI 5M7 5RE 5S5 70F 7X7 85S 88A 88E 88I 8AO 8FE 8FH 8FI 8FJ 8G5 8R4 8R5 AAEEF AARCD AAYOK AAYZH AAZLF ABAWZ ABCQX ABDBF ABDPE ABEFU ABJNI ABLJU ABOCM ABUWG ACBWK ACGFO ACGFS ACGOD ACIWK ACMJI ACPRK ACUHS ADBBV ADFRT AENEX AEUYN AFBBN AFKRA AFRAH AFSHS AGAYW AGCDD AGHTU AHBCP AHMBA AHOSX AHSBF AIBTJ ALFFA ALIPV ALMA_UNASSIGNED_HOLDINGS AMTXH ARMCB ASPBG AVWKF AXYYD AZFZN AZQEC B0M BBNVY BENPR BHPHI BKKNO BPHCQ BVXVI C6C CCPQU CS3 DB5 DU5 DWQXO EAD EAP EBC EBD EBS EE. EJD EMB EMK EMOBN EPL ESX EXGXG F5P FEDTE FQGFK FSGXE FYUFA GNUQQ GUQSH GX1 HCIFZ HMCUK HVGLF HZ~ IAO IEA IH2 IHR IHW INH INR IOF IOV ISR ITC J5H L7B LGEZI LK8 LOTEE M0L M1P M2O M2P M7P MK0 N9A NADUK NNMJJ NXXTH O9- ODYON P2P PQQKQ PROAC PSQYO Q2X RIG RNS RNT RNTTT RVV SHXYY SIXXV SJN SNYQT SOJ SV3 TAE TAOOD TBHMF TDRGL TSG TUS UKHRP UQL X7M XJT YHZ ZGI ~8M AAYXX ABFSG ACSTC AEZWR AFANA AFFHD AFHIU AGSTI AHWEU AIXLP ALPWD ATHPR CITATION PHGZM PHGZT PJZUB PPXIY PQGLB XRW AETEA CGR CUY CVF ECM EIF NFIDA NPM 7QG 7QL 7QP 7QR 7T5 7TK 7TM 7TO 7U7 7U9 7XB 8FD 8FK C1K FR3 H94 K9. M7N MBDVC P64 PKEHL PQEST PQUKI PRINS Q9U RC3 7X8 PUEGO 5PM |
| ID | FETCH-LOGICAL-c540t-80d4fbe84c7e5c148d679c3eb5bcf02d1af989f7c8133443dca14575015334353 |
| IEDL.DBID | M7P |
| ISICitedReferencesCount | 118 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000749043100001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1078-8956 1546-170X |
| IngestDate | Tue Nov 04 02:00:47 EST 2025 Thu Oct 02 13:44:26 EDT 2025 Mon Oct 06 17:39:37 EDT 2025 Thu Apr 03 06:52:33 EDT 2025 Sat Nov 29 06:02:29 EST 2025 Tue Nov 18 21:36:10 EST 2025 Fri Feb 21 02:37:47 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 2 |
| Language | English |
| License | 2022. The Author(s). Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c540t-80d4fbe84c7e5c148d679c3eb5bcf02d1af989f7c8133443dca14575015334353 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 content type line 14 ObjectType-Feature-3 ObjectType-Evidence Based Healthcare-1 ObjectType-Feature-1 content type line 23 ObjectType-Undefined-3 |
| ORCID | 0000-0001-7366-8974 0000-0001-5805-2469 0000-0002-1644-0006 0000-0001-8083-247X |
| OpenAccessLink | https://pubmed.ncbi.nlm.nih.gov/PMC8863573 |
| PMID | 35087233 |
| PQID | 2631747844 |
| PQPubID | 33975 |
| PageCount | 9 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_8863573 proquest_miscellaneous_2623894882 proquest_journals_2631747844 pubmed_primary_35087233 crossref_primary_10_1038_s41591_021_01677_z crossref_citationtrail_10_1038_s41591_021_01677_z springer_journals_10_1038_s41591_021_01677_z |
| PublicationCentury | 2000 |
| PublicationDate | 2022-02-01 |
| PublicationDateYYYYMMDD | 2022-02-01 |
| PublicationDate_xml | – month: 02 year: 2022 text: 2022-02-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | New York |
| PublicationPlace_xml | – name: New York – name: United States |
| PublicationTitle | Nature medicine |
| PublicationTitleAbbrev | Nat Med |
| PublicationTitleAlternate | Nat Med |
| PublicationYear | 2022 |
| Publisher | Nature Publishing Group US Nature Publishing Group |
| Publisher_xml | – name: Nature Publishing Group US – name: Nature Publishing Group |
| References | Juno, Wheatley (CR20) 2021; 27 Dong, Du, Gardner (CR1) 2020; 20 CR17 Halperin (CR3) 2022; 399 CR13 Lustig (CR28) 2021; 9 Logunov (CR22) 2020; 396 Ramshaw, Ramsay (CR16) 2000; 21 Sallusto, Lanzavecchia, Araki, Ahmed (CR21) 2010; 33 Zhu (CR11) 2020; 396 Excler, Kim (CR9) 2019; 18 CR2 CR4 Logunov (CR23) 2021; 397 Jara (CR19) 2021; 385 CR6 He (CR10) 2021; 10 Tanriover (CR18) 2021; 398 CR5 CR8 CR7 Lu (CR14) 2009; 21 CR29 CR26 Kardani, Bolhassani, Shahbazi (CR15) 2016; 34 CR25 CR24 Shaw (CR27) 2021; 397 Kristiansen (CR12) 2021; 397 S Lu (1677_CR14) 2009; 21 E Dong (1677_CR1) 2020; 20 1677_CR17 1677_CR13 JL Excler (1677_CR9) 2019; 18 Y Lustig (1677_CR28) 2021; 9 Q He (1677_CR10) 2021; 10 1677_CR8 1677_CR7 K Kardani (1677_CR15) 2016; 34 1677_CR6 1677_CR5 1677_CR4 1677_CR2 IA Ramshaw (1677_CR16) 2000; 21 A Jara (1677_CR19) 2021; 385 1677_CR25 F Sallusto (1677_CR21) 2010; 33 1677_CR26 FC Zhu (1677_CR11) 2020; 396 MD Tanriover (1677_CR18) 2021; 398 DY Logunov (1677_CR23) 2021; 397 SA Halperin (1677_CR3) 2022; 399 DY Logunov (1677_CR22) 2020; 396 1677_CR24 1677_CR29 JA Juno (1677_CR20) 2021; 27 RH Shaw (1677_CR27) 2021; 397 PA Kristiansen (1677_CR12) 2021; 397 |
| References_xml | – volume: 34 start-page: 413 year: 2016 end-page: 423 ident: CR15 article-title: Prime–boost vaccine strategy against viral infections: mechanisms and benefits publication-title: Vaccine doi: 10.1016/j.vaccine.2015.11.062 – volume: 10 start-page: 629 year: 2021 end-page: 637 ident: CR10 article-title: Heterologous prime–boost: breaking the protective immune response bottleneck of COVID-19 vaccine candidates publication-title: Emerg. Microbes Infect. doi: 10.1080/22221751.2021.1902245 – volume: 385 start-page: 875 year: 2021 end-page: 884 ident: CR19 article-title: Effectiveness of an inactivated SARS-CoV-2 vaccine in Chile publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa2107715 – volume: 9 start-page: 999 year: 2021 end-page: 1009 ident: CR28 article-title: BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers publication-title: Lancet Respir. Med. doi: 10.1016/S2213-2600(21)00220-4 – ident: CR4 – ident: CR2 – volume: 21 start-page: 163 year: 2000 end-page: 165 ident: CR16 article-title: The prime–boost strategy: exciting prospects for improved vaccination publication-title: Immunol. Today doi: 10.1016/S0167-5699(00)01612-1 – volume: 33 start-page: 451 year: 2010 end-page: 463 ident: CR21 article-title: From vaccines to memory and back publication-title: Immunity doi: 10.1016/j.immuni.2010.10.008 – volume: 397 start-page: 671 year: 2021 end-page: 681 ident: CR23 article-title: Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime–boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia publication-title: Lancet doi: 10.1016/S0140-6736(21)00234-8 – ident: CR6 – ident: CR29 – ident: CR8 – volume: 27 start-page: 1874 year: 2021 end-page: 1875 ident: CR20 article-title: Boosting immunity to COVID-19 vaccines publication-title: Nat. Med. doi: 10.1038/s41591-021-01560-x – ident: CR25 – volume: 21 start-page: 346 year: 2009 end-page: 351 ident: CR14 article-title: Heterologous prime–boost vaccination publication-title: Curr. Opin. Immunol. doi: 10.1016/j.coi.2009.05.016 – volume: 396 start-page: 479 year: 2020 end-page: 488 ident: CR11 article-title: Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial publication-title: Lancet doi: 10.1016/S0140-6736(20)31605-6 – volume: 396 start-page: 887 year: 2020 end-page: 897 ident: CR22 article-title: Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime–boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia publication-title: Lancet doi: 10.1016/S0140-6736(20)31866-3 – volume: 397 start-page: 2043 year: 2021 end-page: 2046 ident: CR27 article-title: Heterologous prime–boost COVID-19 vaccination: initial reactogenicity data publication-title: Lancet doi: 10.1016/S0140-6736(21)01115-6 – ident: CR17 – volume: 399 start-page: 237 year: 2022 end-page: 248 ident: CR3 article-title: Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-controlled phase 3 trial publication-title: Lancet doi: 10.1016/S0140-6736(21)02753-7 – ident: CR13 – volume: 398 start-page: 213 year: 2021 end-page: 222 ident: CR18 article-title: Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey publication-title: Lancet doi: 10.1016/S0140-6736(21)01429-X – volume: 18 start-page: 765 year: 2019 end-page: 779 ident: CR9 article-title: Novel prime–boost vaccine strategies against HIV-1 publication-title: Expert Rev. Vaccines doi: 10.1080/14760584.2019.1640117 – ident: CR5 – ident: CR7 – volume: 397 start-page: 1347 year: 2021 end-page: 1348 ident: CR12 article-title: WHO International Standard for anti-SARS-CoV-2 immunoglobulin publication-title: Lancet doi: 10.1016/S0140-6736(21)00527-4 – ident: CR26 – ident: CR24 – volume: 20 start-page: 533 year: 2020 end-page: 534 ident: CR1 article-title: An interactive web-based dashboard to track COVID-19 in real time publication-title: The Lancet Infect. Dis. doi: 10.1016/S1473-3099(20)30120-1 – volume: 20 start-page: 533 year: 2020 ident: 1677_CR1 publication-title: The Lancet Infect. Dis. doi: 10.1016/S1473-3099(20)30120-1 – ident: 1677_CR13 doi: 10.1101/2021.10.10.21264827 – ident: 1677_CR5 – volume: 397 start-page: 2043 year: 2021 ident: 1677_CR27 publication-title: Lancet doi: 10.1016/S0140-6736(21)01115-6 – volume: 21 start-page: 163 year: 2000 ident: 1677_CR16 publication-title: Immunol. Today doi: 10.1016/S0167-5699(00)01612-1 – volume: 21 start-page: 346 year: 2009 ident: 1677_CR14 publication-title: Curr. Opin. Immunol. doi: 10.1016/j.coi.2009.05.016 – ident: 1677_CR2 doi: 10.2139/ssrn.3822780 – ident: 1677_CR6 doi: 10.1016/S2666-5247(21)00177-4 – ident: 1677_CR17 doi: 10.1016/j.eclinm.2021.101036 – ident: 1677_CR4 – volume: 33 start-page: 451 year: 2010 ident: 1677_CR21 publication-title: Immunity doi: 10.1016/j.immuni.2010.10.008 – ident: 1677_CR24 doi: 10.1016/S0140-6736(21)01694-9 – ident: 1677_CR26 doi: 10.1056/NEJMc2110716 – volume: 399 start-page: 237 year: 2022 ident: 1677_CR3 publication-title: Lancet doi: 10.1016/S0140-6736(21)02753-7 – volume: 396 start-page: 887 year: 2020 ident: 1677_CR22 publication-title: Lancet doi: 10.1016/S0140-6736(20)31866-3 – volume: 18 start-page: 765 year: 2019 ident: 1677_CR9 publication-title: Expert Rev. Vaccines doi: 10.1080/14760584.2019.1640117 – volume: 397 start-page: 1347 year: 2021 ident: 1677_CR12 publication-title: Lancet doi: 10.1016/S0140-6736(21)00527-4 – volume: 398 start-page: 213 year: 2021 ident: 1677_CR18 publication-title: Lancet doi: 10.1016/S0140-6736(21)01429-X – volume: 9 start-page: 999 year: 2021 ident: 1677_CR28 publication-title: Lancet Respir. Med. doi: 10.1016/S2213-2600(21)00220-4 – volume: 396 start-page: 479 year: 2020 ident: 1677_CR11 publication-title: Lancet doi: 10.1016/S0140-6736(20)31605-6 – volume: 10 start-page: 629 year: 2021 ident: 1677_CR10 publication-title: Emerg. Microbes Infect. doi: 10.1080/22221751.2021.1902245 – ident: 1677_CR7 doi: 10.1016/s1473-3099(21)00681-2 – ident: 1677_CR8 doi: 10.1093/cid/ciab845 – volume: 385 start-page: 875 year: 2021 ident: 1677_CR19 publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa2107715 – volume: 397 start-page: 671 year: 2021 ident: 1677_CR23 publication-title: Lancet doi: 10.1016/S0140-6736(21)00234-8 – ident: 1677_CR25 doi: 10.1101/2021.05.19.21257334 – volume: 34 start-page: 413 year: 2016 ident: 1677_CR15 publication-title: Vaccine doi: 10.1016/j.vaccine.2015.11.062 – volume: 27 start-page: 1874 year: 2021 ident: 1677_CR20 publication-title: Nat. Med. doi: 10.1038/s41591-021-01560-x – ident: 1677_CR29 doi: 10.1007/978-3-642-14691-6 |
| SSID | ssj0003059 |
| Score | 2.6654868 |
| Snippet | The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants and the waning of vaccine-elicited neutralizing antibodies suggests that... |
| SourceID | pubmedcentral proquest pubmed crossref springer |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 401 |
| SubjectTerms | 631/250/2152/2153/1291 631/250/590/1883 692/308/2779/109/1943 Adenoviridae - immunology Adenoviruses Adolescent Adult Adults Antibodies Antibodies, Neutralizing - blood Antibodies, Viral - blood Biomedical and Life Sciences Biomedicine Cancer Research China Coronaviruses COVID-19 COVID-19 - immunology COVID-19 - prevention & control COVID-19 vaccines COVID-19 Vaccines - adverse effects COVID-19 Vaccines - immunology Female Homology Humans Immunization Immunization, Secondary Immunogenicity Immunogenicity, Vaccine - immunology Immunoglobulin G - blood Infectious Diseases Injection Site Reaction - pathology Male Metabolic Diseases Middle Aged Molecular Medicine Neurosciences Neutralizing SARS-CoV-2 - immunology Severe acute respiratory syndrome coronavirus 2 Side effects T-Lymphocytes - immunology Vaccination Vaccines Vaccines, Inactivated - immunology Viral diseases Young Adult |
| Title | Heterologous AD5-nCOV plus CoronaVac versus homologous CoronaVac vaccination: a randomized phase 4 trial |
| URI | https://link.springer.com/article/10.1038/s41591-021-01677-z https://www.ncbi.nlm.nih.gov/pubmed/35087233 https://www.proquest.com/docview/2631747844 https://www.proquest.com/docview/2623894882 https://pubmed.ncbi.nlm.nih.gov/PMC8863573 |
| Volume | 28 |
| WOSCitedRecordID | wos000749043100001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVPQU databaseName: Biological Science Database customDbUrl: eissn: 1546-170X dateEnd: 20241207 omitProxy: false ssIdentifier: ssj0003059 issn: 1078-8956 databaseCode: M7P dateStart: 20200101 isFulltext: true titleUrlDefault: http://search.proquest.com/biologicalscijournals providerName: ProQuest – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1546-170X dateEnd: 20241207 omitProxy: false ssIdentifier: ssj0003059 issn: 1078-8956 databaseCode: 7X7 dateStart: 20200101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1546-170X dateEnd: 20241207 omitProxy: false ssIdentifier: ssj0003059 issn: 1078-8956 databaseCode: BENPR dateStart: 20200101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Research Library customDbUrl: eissn: 1546-170X dateEnd: 20241207 omitProxy: false ssIdentifier: ssj0003059 issn: 1078-8956 databaseCode: M2O dateStart: 20200101 isFulltext: true titleUrlDefault: https://search.proquest.com/pqrl providerName: ProQuest – providerCode: PRVPQU databaseName: Science Database customDbUrl: eissn: 1546-170X dateEnd: 20241207 omitProxy: false ssIdentifier: ssj0003059 issn: 1078-8956 databaseCode: M2P dateStart: 20200101 isFulltext: true titleUrlDefault: https://search.proquest.com/sciencejournals providerName: ProQuest |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3db9MwED-xDdBe-BiDBUZlJN4gWpo4scMLGmXTHlhXIZj6FjlnR620JWXpkOhfz9n5GGViL7xYiu04ce7s-13ufAfwVqc8NBITX6VK-hxV7hM4kr5ElIVKA5M3QVy_iPFYTqfppP3hVrduld2e6DZqXaH9R34QJiTpuJCcf1z88G3WKGtdbVNobMCWjZIQOde9Sb8TEy-njc8hPZwUgfbQTBDJg5oEl_X5Ca0ynQjhr9YF0y20edtp8i_LqRNIx4__dypP4FELRdlhwztP4Z4pd-BBk5zy1w48PG3N7s9gdmKdZmx9dV2zw8-xX47Oztnigq5GNgSCOlfIrIMHVcyqy67nH20KaSjHBR-YYiQgdXU5XxnNFjOSo4wzlz5kF74fH30bnfhtigYfCeotSb5pXuRGchQmRlKtdCJSjEwe51gEoR6qIpVpIVCSLsx5pFENOSHEwMJMQmrRc9gsq9LsATNDpRMkAKFp6IIYRamkIGUyjJXCOEAPhh19Mmzjl9s0GheZs6NHMmtomhFNM0fTbOXBu_6eRRO9487e-x29snYl19kNsTx40zfTGrSGFVUa-prUh4BPSlth6MGLhkv6x0WEgEUYRR6INf7pO9j43ust5Xzm4nxLaYMF0p3vO067ea1_z-Ll3bN4BduhPcHhHM_3YXN5dW1ew338uZzXVwPYEFPhSjmArU9H48lXujoNz1w5Gbj19RsMpCdm |
| linkProvider | ProQuest |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9QwEB5V5XnhUaANFDASnGjUrOMkNhJC1ZZqq26XHkrVW3BsR7tSmyzNFtT9UfxGxs6jLBW99cAxsfOw83n8Tfx5BuCtFowarmJfCsl9pmTmIzniPleK51IEJquDuA6T0YgfH4uDJfjV7oWxssrWJjpDrUtl_5Fv0hhnOpZwxj5Nv_s2a5RdXW1TaNSw2DMXP9Flqz7ubuP3fUfpzufD_sBvsgr4CtnJDE2yZnlmOFOJiRR6AzpOhApNFmUqD6juyVxwkSeKo_vGWKiV7DEkNYFlRsxliUCTfwtpBOVOKnjQWX4cO6LWOGJj0fFoNukEId-scKK0GiNqnfc4Sfz54kR4hd1eFWn-tVLrJsCdh_9b1z2CBw3VJlv12HgMS6ZYgTt18s2LFbi738gKnsB4YEVB9nx5XpGt7cgv-l-OyPQEj_o2xIM8kopYAQueGJenbc0_yqTCWzmUfyCSIAHQ5elkbjSZjpEnEEZcepSn8PVGWvwMlouyMGtATE_qWCFB0njrHAeClHGOzjKNpFRRoDzotXhIVROf3aYJOUmdTiDkaY2hFDGUOgylcw_ed9dM6-gk19Zeb_GRNpaqSi_B4cGbrhhtjF04koXB3sQ6SOwEmnrqwWqNyu5xITL8hIahB8kCXrsKNn75YkkxGbs45pzbYIh45UaL7MvX-ncrnl_fitdwb3C4P0yHu6O9F3Cf2t0qTmS_Dsuzs3PzEm6rH7NJdfbKjV0C324a8b8BxMt9qg |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1bb9MwFD6aBky8cBm3wAAjwRNETR0ndpAQmlqqTRulDzDtLXNsR620JWXpQOtP49dx7FxGmdjbHnhM7Fycfj7nO_XncwBe64RRI1Tsy0QKnymZ-UiOhC-UErlMApPVSVz3-XgsDg-TyRr8avfCWFllaxOdodalsv-R92iMno5xwVgvb2QRk-Ho4_y7bytI2ZXWtpxGDZE9c_4Tw7fqw-4Qf-s3lI4-fR3s-E2FAV8hU1mgedYsz4xgiptIYWSgY56o0GRRpvKA6r7ME5HkXAkM5RgLtZJ9hgQnsCyJuYoRaP5vcJu03MkGJ50XwHmU1HpHHDgGIc2GnSAUvQqdptUbURvIx5z7y1WneInpXhZs_rVq65zh6O7__BnvwZ2GgpPtes7chzVTbMKtuijn-SZsfG7kBg9gumPFQvZ8eVaR7WHkF4MvB2R-jEcDm_pBHkhFrLAFT0zLk7bnH21S4a0c-t8TSZAY6PJktjSazKfIHwgjrmzKQ_h2LSN-BOtFWZgnQExf6lghcdJ46xwniJRxjkE0jaRUUaA86LfYSFWTt92WDzlOnX4gFGmNpxTxlDo8pUsP3nbXzOusJVf23mqxkjYWrEovgOLBq64ZbY9dUJKFwa-JfZDwJegCqAePa4R2jwuR-XMahh7wFex2HWxe89WWYjZ1-c2FsEkS8cp3LcovXuvfo3h69ShewgYCPd3fHe89g9vUbmJx2vstWF-cnpnncFP9WMyq0xduGhM4um7A_wZm-IZn |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Heterologous+AD5-nCOV+plus+CoronaVac+versus+homologous+CoronaVac+vaccination%3A+a+randomized+phase+4+trial&rft.jtitle=Nature+medicine&rft.au=Li%2C+Jingxin&rft.au=Hou%2C+Lihua&rft.au=Guo%2C+Xiling&rft.au=Jin%2C+Pengfei&rft.date=2022-02-01&rft.eissn=1546-170X&rft.volume=28&rft.issue=2&rft.spage=401&rft_id=info:doi/10.1038%2Fs41591-021-01677-z&rft_id=info%3Apmid%2F35087233&rft.externalDocID=35087233 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1078-8956&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1078-8956&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1078-8956&client=summon |